Navigation Links
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Date:6/8/2009

collaboration with the Netherlands Cancer Institute. The lead investigator was Marcel Verheij, MD, Ph.D., Head of the Department of Radiation Oncology and group leader at the Division of Cell Biology of The Netherlands Cancer Institute in Amsterdam. In all, 22 study sites in The Netherlands, Bulgaria, Romania, Macedonia, and Belarus participated in this trial.

Results

A total of 177 patients were randomized and treated, of whom only 26 reached the milestone of one year post-treatment follow-up without disease relapse or progression, 14 of 95 patients (14.7%) in the perifosine and 12 of 82 patients (14.6%) in the placebo control group. No difference between treatment groups could be shown for local, loco-regional and overall disease control. Also the tumor response rate, as assessed after the end of the radiotherapy, was not different between the groups.

In contrast to the lack of an observed local effect, patients in the perifosine group, particularly the subgroup of patients who entered the study without prior chemotherapy, showed a trend towards longer survival than patients of the placebo control group despite the short duration of treatment (5-week course of 150 mg perifosine daily).

There were no safety signals that would lead to an amendment of the current safety data or risk benefit assessments of perifosine. The type and severity of side effects were in the expected range.

Marcel Verheij, M.D., Ph.D., lead investigator, "The neutral outcome of this study is related to the unexpectedly high number of distant failures and premature discontinuations for other reasons, which heavily compromised the power of the study to show any effect on the local control rate at one year."

Paul Blake, M.D., Senior Vice President and Chief Medical Officer at AEterna Zentaris,"In light of these neutral results and an unchanged safety profile, we can concentrate our efforts on the disease targets of both multiple m
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets has announced the addition ... report to their offering. ... the designing and engineering of completely new biological parts, ... natural biological systems that provide improved and desirable functions. ... genetic engineering because it not only alters existing metabolic ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ -   JOLT ... group of companies to join its growing portfolio of ... of Toronto,s JOLT accelerator, and ... on the roster. Since its launch ... have successfully raised  $7.5M of financing. Now at 23 ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3
... -- Children's Hospital and Health System ... the Eclipsys Sunrise Clinical Manager advanced clinical information ... to Eclypsis Corp, of Boca Raton, ... ED Manager, Pharmacy Benefits Manager, Sunrise Secure Health ...
... - The two-year state budget signed into law Monday ... of many Wisconsin technology firms by changing how corporate ... Wisconsin Technology Council. , ,With bipartisan support ... the "single-sales factor" sales apportionment for corporate income to ...
... - The average citizen may think Gov. Jim Doyle and ... step into the boxing ring of politics. And judging by ... the Capitol over the past two and a half years, ... entirely correct, however, as evidenced by some important tax changes ...
Cached Biology Technology:`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3State tax compromises prove that partisanship can be set aside for a while 2State tax compromises prove that partisanship can be set aside for a while 3
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
(Date:7/28/2014)... Kansas He calls himself the bug hunter, but ... can only be found and identified with special methods ... the Kansas State Veterinary Diagnostic Laboratory at Kansas State ... discoveries, porcine enterovirus G, which is an important find ... virus in cells, but didn,t know what it was," ...
(Date:7/28/2014)... that 73 percent of adult survivors of childhood cancer ... and related health problems by failing to follow a ... of the journal Cancer . , Almost 32 ... in the study had metabolic syndrome, an umbrella term ... obesity, elevated triglyceride and other abnormalities that often occur ...
Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... Supply Chain Council (SCC) announced today ... Operations Management to offer a unique new program that ... and operations management professionals.SCC is the world,s leading authority ... the SCOR(R) standard while APICS is the leader in ...
... Military and civilian personnel from the U.S. Armed Forces, ... law enforcement and other first-responder personnel from throughout the ... register and attend the 2009 Force Protection Equipment Demonstration ... Regional Airport and Marine Corps Base, Quantico, VA, during ...
... Industry Leading Providers Team Up to Provide High ... and InsuranceREDWOOD SHORES, Calif. and NEW YORK, May ... (OTC Bulletin Board: CICI), a leading supplier of ... the financial industry* and the recognized leader** in ...
Cached Biology News:Supply Chain Council Partners With APICS The Association for Operations Management 2Demonstration Features Commercial Technology for Combating Terrorism 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 2Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 3Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 4Striata and CIC Launch Integrated eSignature, eDelivery, and eBilling for the Financial Services Industry 5
... PLAU N-term Antibody This antibody is ... conjugated synthetic peptide selected within aa 50~150 ... supplied in PBS with 0.09% (W/V) sodium ... protein G column and eluted out with ...
... amino acid polypeptide sequence corresponding to Tyr89 ... Produced by activation of a recombinant soluble ... periplasm. SPECIFIC ACTIVITY:The specific activity of ... where 1 U is the activity that ...
... high current power supply capable of producing up ... an excellent choice for PAGE, SDS-PAGE and DNA ... for all types of electroblotting applications.A dual function ... a run and wil automatically accrue elapsed time ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Biology Products: